<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[앰코 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=12797></link><description><![CDATA[앰코 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Mon, 13 Jul 2026 15:35:58 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2009/11/2039103817_20091120175702_7140424088.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[AmKor and Hengdian Group signed Development & Commercialization License for Neu2000, a drug candidate for multiple diseases including stroke and acute myocardial infarction, in China]]></title><link>https://www.newswire.co.kr/newsRead.php?no=442148</link><description><![CDATA[수원--(뉴스와이어)--AmKor (AmKor Pharma, Inc.) and Hengdian Group (Hengdian Group Ltd) today announced the signing of licensing agreement for further development and commercialization of Neu2000 in China.  Under the agreement terms, Hengdian Group will pay RMB 5 million Yuan as a research fund for the study of acute myocardial infarction (AMI) and burns immediately...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2009/11/2039103817_20091124102534_1212744185.jpg]]></url></image><pubDate>Tue, 24 Nov 2009 10:27:25 +0900</pubDate></item><item><title><![CDATA[앰코-중국 헹디안(橫店)그룹 쟈웬, 뇌졸중 및 심근경색 신약 ‘Neu2000’ 기술이전계약 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=441969</link><description><![CDATA[수원--(뉴스와이어)--지난 11 년간 (주)뉴로테크에서 뇌졸중, 심근경색, 화상, 척수손상 치료제로 개발해온 Neu2000이 중국 헹디안그룹에 기술이전 되었다.   기술이전계약은 (주)뉴로테크의 미주법인인 앰코(대표이사 곽병주)와 헹디안그룹 제약사인 쟈웬(家圓, 대표이사 徐新良)에 의해 체결되었으며, 계약에 따라 쟈웬은 500만 위안을 뉴로테크에서 진행중인 Neu2000의 심근경색 및 화상 연구...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2009/11/2039103817_20091123142049_7202276000.jpg]]></url></image><pubDate>Mon, 23 Nov 2009 14:21:43 +0900</pubDate></item></channel></rss>